Five-year relative survival for lung cancer caught while still localised is 65.5%. For disease that has spread to distant sites it is 10.5%. That gap — wider than in almost any other common cancer — is the reason lung cancer files behave differently from the rest of the category.
Our cancer history page covers how a cancer diagnosis is assessed generally. This page is about lung specifically, and about the two things that make it distinct: the extremity of the stage separation, and smoking.
Stage is not one factor among several
In most conditions an underwriter weighs half a dozen inputs. In lung cancer, stage at diagnosis dominates so heavily that the rest of the file often only decides where within a narrow band you land.
SEER’s figures for 2016–2022 give five-year relative survival as 65.5% localised, 38.2% regional, 10.5% distant, and 29.5% across all stages. (SEER)
A carrier pricing a twenty-year term policy cannot bridge a spread that large with a surcharge. What it does instead is treat the stages as effectively different conditions, which is why the practical outcomes diverge so sharply:
- Stage I, resected, several years clear, non-smoker. Traditional cover is genuinely obtainable, usually with a rating and sometimes with a flat extra that falls away after a set number of years.
- Stage II or III. Longer postpone periods, and offers that come with substantial loading when they come at all. Carrier appetite varies enormously here.
- Stage IV. Fully underwritten cover is generally not available. Guaranteed issue and final expense are the realistic products.
If you do not know your stage and histology as recorded at diagnosis, that is the first thing to obtain. Everything else on the application is secondary to it.
Small cell and non-small cell are underwritten separately
Non-small cell lung cancer — adenocarcinoma, squamous cell, large cell — accounts for the large majority of diagnoses and has the more established underwriting path. Small cell lung cancer is more aggressive, is usually diagnosed at a later stage, and is treated more cautiously by carriers even at apparently comparable stages.
Carcinoid tumours of the lung are a third category again and are frequently underwritten far more favourably than either. If you have one, make sure the application says so rather than letting it be read as lung cancer generically.
Smoking compounds rather than adds
This is the part that separates lung cancer from breast, prostate or colon cancer in an underwriter’s hands.
For most conditions, smoking is priced as a separate factor and then combined. With lung cancer it is read as bearing directly on recurrence and on second primary risk. Continuing to smoke after a lung cancer diagnosis is, in underwriting terms, one of the strongest negative signals available — it takes files that would otherwise have been rateable and moves them out of traditional cover entirely.
The converse holds. Documented cessation, with a date, materially changes the file. Most carriers use twelve months as the threshold for non-smoker rates, and look further back for their better classes. For a lung cancer applicant, the quit date is one of the few variables still under your control, and it is worth more than any comparison shopping.
Never-smokers with lung cancer — a growing share of diagnoses, particularly adenocarcinoma in younger women — occupy an unusual position. The file lacks the compounding factor, and practitioners report it is underwritten more favourably than the stage alone would suggest.
The postpone period, and what it is for
No carrier will consider a fully underwritten application during active treatment. After treatment ends, a postpone period applies before the file can be assessed at all.
That period is longer for lung cancer than for most diagnoses, and it scales with stage. Practitioners commonly report several years for early-stage disease and considerably longer for later stages, with the better classes reserved for applicants many years clear. Those are conventions rather than published thresholds — carrier manuals are not public, for the reasons set out on our how underwriting works page.
What the postpone period is measuring is recurrence risk, which is concentrated early. It is not a punishment and it is not negotiable, but it is finite, and time genuinely improves the file in a way that little else does.
What to have documented
- The pathology report — histology and stage as recorded at diagnosis
- Treatment summary — surgery, chemotherapy, radiation, immunotherapy or targeted therapy, with dates
- Date treatment ended. This starts the clock, and it is the date carriers count from
- Surveillance imaging — the most recent scan report, and the interval you are on
- Smoking history — pack-years, and the quit date if applicable
- Current oncology follow-up — a recent note confirming no evidence of disease
Supplying these up front frequently avoids an Attending Physician’s Statement request, which otherwise adds weeks.
Cover in the meantime
During treatment and during the postpone period, traditional underwriting is closed. That does not mean nothing is available.
Guaranteed issue asks no health questions, issues quickly, and carries a graded death benefit for the first two or three years. Face amounts are small. It is a bridge rather than a solution, and holding it does not stop you applying properly later — a point worth making because people often assume the two are mutually exclusive.
Group cover through an employer is also issued without individual underwriting up to the guaranteed amount, and is the most overlooked option in this category. Check what you already have before buying anything.
What to do next
Get your pathology report and the date treatment ended. Those two documents determine which of the paths above you are on, and no amount of shopping around substitutes for knowing them.
If you are inside the postpone window, bridge with guaranteed issue if you need cover now, and use the interval to accumulate clean surveillance scans. If you are past it, apply through someone who knows which carriers write post-cancer files, and expect wide variation between them — a single decline in this category is close to meaningless, which is what our page on applying after a decline is about.